Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Adalimumab | Uveitis - non-infectious (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Aflibercept | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Aflibercept | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Bevacizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Bevacizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Biologic and Biosimilar Medicines | Where indicated | n/a | Patient information | Hertfordshire and West Essex ICB |
Blepharoplasty and Brow Lift | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Blepharoplasty and Brow Lift Prior Approval Form | n/a | Prior approval form | Hertfordshire and West Essex ICB | |
Brolucizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Brolucizumab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Cataract Surgery | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Chalazia (meibomian cysts) removal | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Chalazia Prior Approval Form | n/a | Prior approval form | Hertfordshire and West Essex ICB | |
Ciclosporin eye drops | Dry eye disease that has not improved despite treatment with artificial tears | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dexamethasone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dexamethasone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dry Eye Disease | Dry eye disease | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Dry eye lubrication drops & gels – frequently asked questions. | Dry eye disease | n/a | Patient information | Hertfordshire and West Essex ICB |
Dysthyroid Eye Disease | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Faricimab | Visual impairment caused by macular oedema after retinal vein occlusion | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Faricimab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Faricimab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Fluocinolone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fluocinolone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Lutein and Antioxidants | Eye Supplements for AMD | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Lutein and Antioxidants Patient Information Leaflet | Eye Supplements for AMD | n/a | Patient information | Hertfordshire and West Essex ICB |
Mercaptamine | Corneal cystine deposits (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Ocriplasmin | Vitreomacular traction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ranibizumab | Diabetic retinopathy | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ranibizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Ranibizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Wet AMD | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |